Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 3/20 | 0.35 |
| ▸ | ELOC | Q15369 | 2/20 | 0.35 |
| ▸ | ELOB | Q15370 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24068291 | 0.92 | VHL (0.37) | VHLELOCELOBELANEHRH3 | |
| SCHEMBL13161235 | 0.85 | NPSR1 (0.36) | ELANEDPP4DPP8DPP9FAP | |
| SCHEMBL24047853 | 0.84 | ELANE (0.37) | ELANEDPP4DPP8DPP9FAP | |
| SCHEMBL25893240 | 0.82 | ITGB3 (0.33) | VHLELOCELOBELANESTAT6 | |
| SCHEMBL20231569 | 0.82 | HRH2 (0.38) | ALDH1A1 | |
| SCHEMBL25893829 | 0.81 | PRMT5 (0.36) | VHLELOCELOBHSD17B10 | |
| SCHEMBL22297348 | 0.80 | VHL (0.32) | VHLELOCELOBHRH3DPP4 | |
| SCHEMBL13073346 | 0.79 | DPP4 (0.35) | ELANEDPP4DPP8DPP9FAP | |
| SCHEMBL18754696 | 0.79 | DPP4 (0.35) | ELANEDPP4DPP8DPP9FAP | |
| SCHEMBL25855935 | 0.79 | PREP (0.41) | ELANEDPP4DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | VHL 1029/4885ELOC 1461/4885ELOB 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.